OR WAIT null SECS
Novartis revealed results from two new clinical trials indicating that Entresto (sacubitril/valsartan) significantly improves measures of cardiac structure and function in heart failure with reduced ejection fraction.
In a Sep. 2, 2019 press release, Novartis revealed results from two new clinical trials, PROVE-HF and EVALUATE-HF, indicating that Entresto (sacubitril/valsartan) significantly improves measures of cardiac structure and function in heart failure with reduced ejection fraction (HFrEF).
Study results showed the ability of Entresto to positively impact a biomarker that is known to be linked to the prognosis of clinical outcomes in HFrEF. As a result of this correlation, improvements in structural and functional changes to the heart (cardiac remodeling) were seen. As cardiac remodeling occurs with HFrEF and can be detrimental to the heart’s functionality, a positive impact on this side effect is anticipated to be important in treatment and may offer damage reversal to the heart, improving potential clinical outcomes.
“The PROVE-HF and EVALUATE-HF studies provide the first evidence that Entresto may help reverse the damage to the heart caused by HFrEF, which could lead to improved clinical outcomes,” said Marcia Kayath, global head medical affairs and chief medical officer, Novartis Pharmaceuticals. “As part of our commitment to reimagining heart failure treatment, we conducted these studies to more deeply understand Entresto’s impact on heart structure and function in HFrEF patients. For the first time, an association was shown between a biomarker and cardiac remodeling improvements in patients treated with Entresto.”
Results from the Phase IV studies were presented during the European Society of Cardiology Congress 2019 and have been published in the Journal of the American Medical Association.